Scancell Hldgs Plc Market Cap ($10.58 Million)
Market Cap & Net Worth: Scancell Hldgs Plc (SCLP)
Scancell Hldgs Plc market cap. Scancell Hldgs Plc (LSE:SCLP) has a market capitalization of $10.58 Million (GBX86.97 Billion) as of November 7, 2026. Listed on the LSE stock exchange, this UK-based company holds position #26767 globally and #350 in its home market, demonstrating a -5.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scancell Hldgs Plc's stock price GBX83.80 by its total outstanding shares 1037781403 (1.04 Billion). Also see cash efficiency ratio of Scancell Hldgs Plc for how efficiently the company converts equity into cash flow.
Scancell Hldgs Plc Market Cap History (2015–2026)
Scancell Hldgs Plc market cap history from 2015 to 2026. Data shows growth from $2.70 Million to $10.58 Million (11.84% CAGR). Check Scancell Hldgs Plc (SCLP) stock price for real-time trading data and today's change.
Index Memberships
Scancell Hldgs Plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$992.58 Million | 1.07% | #16 of 722 |
Weight: Scancell Hldgs Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Scancell Hldgs Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scancell Hldgs Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Scancell Hldgs Plc (SCLP) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.27x
Scancell Hldgs Plc's market cap is 0.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $1.33 Million | $5.27 Million | -$11.94 Million | 0.25x | N/A |
| 2025 | $1.25 Million | $4.71 Million | -$12.27 Million | 0.27x | N/A |
Competitor Companies of SCLP by Market Capitalization
Companies near Scancell Hldgs Plc in the global market cap rankings as of November 7, 2026. Also see Scancell Hldgs Plc assets under control for a full breakdown of the balance sheet.
Key companies related to Scancell Hldgs Plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #176 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #405 globally with a market cap of $69.48 Billion USD ( AU$98.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #499 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #176 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $542.50 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $902.90 |
| #405 | CSL Ltd | AU:CSL | $69.48 Billion | AU$202.40 |
| #499 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $241.46 |
Market Capitalization of Scancell Hldgs Plc (2015–2026)
Market capitalization of Scancell Hldgs Plc from 2015 to today. Between 2015 and today, Scancell Hldgs Plc's market cap moved from $2.70 Million to $ 10.58 Million, with a yearly change of 11.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX10.58 Million | +746.46% |
| 2025 | GBX1.25 Million | -7.91% |
| 2024 | GBX1.36 Million | +2.38% |
| 2023 | GBX1.33 Million | -57.58% |
| 2022 | GBX3.13 Million | +23.75% |
| 2021 | GBX2.53 Million | +42.86% |
| 2020 | GBX1.77 Million | +97.25% |
| 2019 | GBX896.21K | -20.55% |
| 2018 | GBX1.13 Million | -28.22% |
| 2017 | GBX1.57 Million | -13.56% |
| 2016 | GBX1.82 Million | -32.74% |
| 2015 | GBX2.70 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Scancell Hldgs Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.58 Million USD |
| MoneyControl | $10.58 Million USD |
| MarketWatch | $10.58 Million USD |
| marketcap.company | $10.58 Million USD |
| Reuters | $10.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scancell Hldgs Plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more